M

oving on from biopharma’s latest setback in Alzheimer’s disease — and the four that preceded it last year — the industry is turning its attention to a tiny pill made by a small company with hopes to succeed where so many have failed.

In the third quarter of this year, Axovant Sciences will release Phase 3 data that will determine whether its drug, intepirdine, can improve cognition and function in patients with mild or moderate Alzheimer’s. Axovant’s readout will follow an outright failure from Merck, disappointing results from Eli Lilly, and a vexing setback for TauRx.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.